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NIDDM patients are consistent with a complex pattern*Research Division
of inheritance. Longitudinal studies indicate that the ear-Joslin Diabetes Center and
liest detectable defect in the pathogenesis of NIDDM isDepartment of Medicine
the inability of tissues such as muscle and fat to respondHarvard Medical School
to normal levels of circulating insulin, i.e., insulin resis-Boston, Massachusetts 02215
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been studied as possible sites of genetically determinedNational Institutes of Health
insulin resistance (Kahn, 1994). The major intracellularBethesda, Maryland 20892
substrates of the insulin receptor tyrosine kinase are
insulin receptor substrates IRS-1 and IRS-2 (Sun et al.,
1991, 1995). IRS molecules become rapidly phosphory-Summary
lated on multiple tyrosine residues upon ligand stimula-
tion and bind a variety of signaling proteins via their src-NIDDM is a polygenic disease characterized by insulin
homology-2 (SH2) domains, including the growth factorresistance in muscle, fat, and liver, followed by a failure
receptor binding protein Grb-2, the p85 regulatory sub-of pancreaticb cells to adequately compensate for this
unit of phosphatidylinositol (PI) 3-kinase and the tyro-resistance despite increased insulin secretion. Mice
sine protein phosphatase Syp/SHPTP 2 (Backer et al.,double heterozygous for null alleles in the insulin re-
1992; Baltensperger et al., 1993; Skolnik et al., 1993;ceptor and insulin receptor substrate-1 genes exhibit
Sun et al., 1993). These signaling molecules bind to IRSsthe expected z50% reduction in expression of these
and are activated, thus mediating a variety of biological
two proteins, but a synergism at a level of insulin resis-
signals such as mitogenesis, glucose transport, and
tance with 5- to 50-fold elevated plasma insulin levels
gene transcription (Waters et al., 1993; Cheatham et al.,and comparable levels of b cell hyperplasia. At 4–6
1994; Rose et al., 1994; Cheatham and Kahn, 1995).months of age, 40% of these double heterozygotes
Compared to other signaling molecules, the IRS-1 gene
become overtly diabetic. This NIDDM mouse model in
is highly polymorphic, exhibiting coding sequence varia-
which diabetes arises in an age-dependent manner
tions in about 5% of normal individuals and between
from the interaction between two genetically deter-
10% and 20% of people with NIDDM (Almind et al.,
mined, subclinical defects in the insulin signaling cas- 1993; Laakso et al., 1994; Ura et al., 1996). Moreover,
cade demonstrates the role of epistatic interactions alterations in the level of expression of both the insulin
in the pathogenesis of common diseases with non- receptor and IRS-1 are observed in humans and rodents
Mendelian genetics. with NIDDM owing to down-regulation at the protein
level (Saad et al., 1992; Bisbis et al., 1993; Goodyear et
Introduction al., 1995).
Naturally occurring animal models, such as the ob/
Noninsulin-dependent diabetes mellitus (NIDDM) is the ob and db/db mouse and the Zucker fatty rat, that have
most common endocrine disorder, affecting over 5% been commonly employed for the analysis of NIDDM do
of the population in western countries, with increasing not appear to accurately mimic the human disease, but
incidence as the population ages and becomes more are models in whichdiabetes occurs secondarily to mas-
sedentary and obese (Warram et al., 1995). A strong sive obesity resulting from mutations of the gene for
genetic component in the etiology of NIDDM is sug- leptin or its receptor (Zhang et al., 1994; Chen et al.,
gested by a very high concordance rate between mono- 1996; Chua, Jr., et al., 1996). We and others have at-
zygotic twins (Newman et al., 1987) and an increased tempted to create new models of NIDDM by eliminating
prevalence of the disorder in first-degree relatives of expression of single proteins in the insulin signaling cas-
affected individuals (Rich, 1990). Thus far, attempts to cade, such as the insulin receptor and IRS-1. However,
identify relevant mutations or polymorphisms that ac- mice deficient for the IR gene exhibit severe insulin resis-
count for this genetic predisposition have met very lim- tance and die from ketoacidosis within 3–7 days after
ited success. Some subtypes of NIDDM, such as syn- birth, and animals lacking IRS-1 are severely growth
dromes of severe insulin resistance or maturity onset retarded (due to IGF-1 resistance) as well as insulin
diabetes in the young (MODY), are due to mutations in resistant. Such severe deficiencies of insulin signaling
proteins are very rare in humans (Wertheimer et al.,the insulin receptor (IR) or the glucokinase genes (Flier,
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1993), and heterozygous animals for both knockouts did
not exhibit an obvious clinical phenotype (Araki et al.,
1994; Tamemoto et al., 1994; Accili et al., 1996; Joshi
et al., 1996).
Therefore, to create a polygenic mouse model for
NIDDM that might more closely mimic the human dis-
ease, we have generated mice with combined heterozy-
gous deficiencies in the IR and IRS-1 genes. These ani-
mals are lean but highly insulin resistant, and 40%
develop NIDDM between the ages of 4 and 6 months,
despite massive hyperinsulinemia and pancreatic b cell
hyperplasia. These animals provide a new understand-
ing of the genetic and molecular mechanisms underlying
NIDDM in which the combination of two mild defects in
the insulin signaling cascade give rise to insulin resis-
tance and subsequent progression to a diabetic phe-
notype.
Results
IR/IRS-1 (1/2) Mice Develop Normally,
While IR/IRS-1 (2/2) Mice Die
from Diabetic Ketoacidosis
Mice double heterozygous for IR and IRS-1 null alleles
were obtained by breeding mice heterozygous for either
mutation alone and identified according to the scheme
outlined in Figure 1A. These IR/IRS-1 (1/2) mice were
born with the expected Mendelian frequency of 25%
and were indistinguishable from wild-type, IRS-1 (1/2),
and IR (1/2) mice. Their extrauterine development pro-
ceeded at normal rates, with a slight, nonsignificant de-
crease in body weight (Figure 1B). Simultaneously, mice
homozygous for null mutations in both genes were cre-
ated by mating male and female IR/IRS-1 double hetero-
zygote mice or IRS-1 (2/2) IR (1/2) male mice with
double heterozygote IR/IRS-1 females. Mice homozy-
gous for the IR null allele, either alone or in combination
with the null allele in the IRS-1 locus, were also born
with the expected frequency. As previously described
for the IR (2/2) mice, animals of these genotypes died
within 72 hr of birth due to uncontrolled diabetes. Blood
glucose concentrations, determined 24 hr after birth,
Figure 1. Creation of IR/IRS-1 Mutant Mice revealed severe hyperglycemia, independent of the
(A) Mice were bred as described in the text. DNA extracted from presence of the IRS-1 mutation (Figure 1C). Likewise,
tail biopsies was subjected to PCR analysis using primers flanking mice homozygous for the IRS-1 null allele, whether alone
the insertion site of the neomycin resistance cassette (IRS1/IRS2) or in combination with the IR null alleles, exhibited intra-
in the IRS-1 gene, primers in intron 3 (IR1) and exon 4 (IR2) of the
uterine growth retardation.IR gene, and primers in exon 4 (IR3) of the IR gene and the neomycin
cassette (IR4), which replaced part of exon 4 in the targeted IR
Heterozygosity for Null Alleles in the IR and IRS-1locus. Presence of the wild-type allele in the IRS-1 gene results in
a 440 bp product, whereas insertion of the neomycin cassette in Gene Results in Synergistic Impairment
the targeted allele results in a band of 1.25 kb (upper panel). Primer of Insulin Signaling
set IR1 and IR2 detect only the wild-type IR allele, since the recogni- To assess the effect of heterozygosity for a null allele
tion site of IR2 is replaced in the targeted allele (middle panel).
in the IR and IRS-1 genes alone or in combination onPrimer set IR3 and IR4 yield only a product in the presence of
protein expression, we performed immunoprecipita-the mutant IR allele, since primer 4 is anchored in the neomycin
tions on liver and muscle extracts from wild-type, IRS-1resistance cassette (bottom panel). Exemplary results are shown
for wild-type (lane 1), IR/IRS-1 (1/2) (lane 2), IRS-1 (2/2)/IR (1/1) (1/2), IR (1/2), and IR/IRS-1 (1/2) mice using anti-IR,
(lane 3), IRS-1 (1/1)/IR (2/2) (lane 4), and IR/IRS-1 (2/2) (lane 5)
mice.
(B) Body weights of wild-type (closed circle), IRS-1 (1/2) (closed
diamond), IR (1/2) (asterisk), and IR/IRS-1 (1/2) (open circle) mice (C) Blood glucose concentrations were determined in wild-type
were determined at the indicated age. Data are presented from at (WT), homozygous insulin receptor–deficient (IR [2/2]), homozy-
least eight animals of each genotype. Values represent the mean gous IRS-1-deficient (IRS-1 [2/2]), and double homozygous mice
body weight; the standard error at each point was ,15% within (IR/IRS-1 [2/2]) mice 16–24 hours after birth. Data shown represent
each group. the mean 1/2 SEM for at least four animals of each genotype.
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anti-IRS-1, anti-IRS-2, and anti-p85 antibodies, followed
by Western blot analysis with the respective antibodies.
If a null allele for IR was present either alone or in combi-
nation with an IRS-1 null allele, expression of IR was
reduced in approximate proportion to gene dosage.
Quantification of multiple experiments showed an z60%
reduction in IR expression in liver (Figure 2A) and muscle
(data not shown) of heterozygote IR (1/2) animals. Simi-
larly, inactivation of one allele of the IRS-1 gene resulted
in an z60% reduction in IRS-1 protein expression (Fig-
ure 2B). As expected, the expression of the alternative
substrate of the insulin receptor kinase, IRS-2, and of
the p85 regulatory subunit of PI 3-kinase was unaltered
by the presence of either the IR or IRS-1 null alleles
(Figure 2C). Short-term administration of insulin had no
effect on the expression of the insulin signaling mole-
cules examined.
To determine the consequence of reduced insulin re-
ceptor and IRS-1 expression on insulin-stimulated sig-
naling, we investigated the early signaling events in both
liver and muscle. In wild-type animals, insulin rapidly
stimulated the tyrosine autophosphorylation of the insu-
lin receptor, and this was unaltered in IRS-1 (1/2) mice
(Figure 3A). In IR (1/2) and IR/IRS-1 (1/2) mice, the
60% reduction of insulin receptor expression led to a
similar reduction in receptor autophosphorylation (Fig-
ure 3A). As with insulin receptor phosphorylation, wild-
type animals also exhibited a robust stimulation of IRS-1
phosphorylation (Figure 3B). Reduction of IRS-1 expres-
sion alone in IRS-1 (1/2) mice or reduction of insulin
receptor alone in IR (1/2) mice led to a 40%–50% re-
duced tyrosine phosphorylation of IRS-1 (Figure 3B). In
double heterozygous animals, combined deficiency of
one copy of the IR and one copy of the IRS-1 gene
led to a 70% reduction of insulin-stimulated tyrosine
phosphorylation of IRS-1 (Figure 3B). Thus, the com-
bined deficiency for the insulin receptor and IRS-1 re-
sulted in an additive effect on impairment of this step
in insulin signaling.
IRS-2 is an alternative substrate of the insulin receptor
kinase and provides a partial compensation for insulin
and IGF-1 (insulin-like growth factor-1) signaling in ho-
mozygous IRS-1-deficient mice (Araki et al., 1994; Patti
et al., 1995). In livers of wild-type mice, IRS-2, like IRS-1,
becomes rapidly tyrosine phosphorylated following in-
sulin administration (Figure 3C). Reduced expression of
IRS-1 in the IRS-1 (1/2) mice led to an z20% increase
in IRS-2 phosphorylation (Figure 3C). Since this occurs
without an increase in IRS-2 expression, this suggests
Figure 2. Expression of Insulin Receptor and IRS-1 in Liver of Differ- that IRS-1 and IRS-2 act as competitive substrates for
ent Mutant Mice the insulin receptor kinase. In contrast, reduced expres-
(A) Liver extracts prepared from wild-type (WT), heterozygous IRS-1 sion of the insulin receptor resulted in a 40% reduction
(IRS-1 [1/2]), heterozygous IR (IR [1/2]), and double heterozygous of IRS-2 phosphorylation, in both the IR (1/2) and IR/
(IR/IRS-1 [1/2]) mice that had been injected with either saline (2) IRS-1 (1/2) mice (Figure 3C). Thus, the double heterozy-
or insulin (1) in the inferior vena cava after an overnight starvation
gote mice exhibited a 40% impairment of both insulinperiod were subjected to immunoprecipitation with an anti-insulin
receptor and IRS-2 phosphorylation due to reduced in-receptor antibody, followed by Western blotting with the same anti-
sulin receptor expression and a 70% reduction in IRS-1body. The upper panel shows a representative experiment; the lower
panel summarizes the quantitation of the results obtained from 4–6
animals of each genotype. The data are expressed as the percent-
age of insulin receptor expression in the wild-type animals. The data (C) Shown is a representative experiment for the expression of IRS-2
are the mean 1/2 SEM. (upper panel) and p85, the regulatory subunit of PI 3-kinase (lower
(B) The experiment was performed as described in (A), with the panel), in liver of the different mutant mice. Immunoprecipitation
exception that immunoprecipitation and Western blotting were per- and Western blotting were performed as described in Experimental
formed with an antibody against IRS-1. Procedures.
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Figure 3. Proximal Steps of Insulin Signaling in Liver of Different Mutant Mice
(A) Insulin-stimulated tyrosine phosphorylation of the b subunit of the insulin receptor was assayed by performing immunoprecipitations using
an anti-insulin receptor antibody on liver extracts from mice that had been injected with either saline (2) or insulin (1) in the inferior vena
cava after an overnight starvation period. Western blot analysis was performed using an anti-phosphotyrosine antibody. The upper panel
shows a representative experiment; the lower panel, the quantitation of results for at least four animals under each experimental condition.
Results are expressed as percentage of the signal intensity detected in the insulin-stimulated wild-type (WT) animal. Open bars indicate values
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phosphorylation due to combined deficiency in both
genes.
IRS-1 and IRS-2 mediate further downstream signal-
ing events by binding to SH2 domain–containing pro-
teins via their tyrosine-phosphorylated motifs. One of
the SH2 proteins implicated in mediating insulin-stimu-
lated glucose transport and other metabolic signals is
the p85 regulatory subunit of PI 3-kinase that binds to
phosphorylated IRS-1, resulting in activation of the p110
catalytical subunit. Association of p85 with IRS-1 was
reduced by 40% in liver of IRS-1 (1/2) mice and IR (1/2)
mice and by 60% in IR/IRS-1 (1/2) mice, paralleling the
decreased IRS-1 phosphorylation in these mice (Figure
3D). In contrast, IRS-2-associated p85 was unaltered in
the IRS-1 (1/2) mice, despite the modest increase in
insulin-stimulated IRS-2 phosphorylation (Figure 3E).
Reduction of insulin receptor expression, on the other
hand, resulted in a 40% reduction in insulin-stimulated Figure 4. Insulin-Stimulated Signaling Events in Muscle of Different
association of IRS-2 with p85, whether the level of IRS-1 Mutant Mice
expression was normal or reduced (Figure 3E). Insulin-stimulated tyrosine phosphorylation of the insulin receptor
(upper panel) and IRS-1 (second panel from the top), as well as
insulin-stimulated association of p85 with IRS-1 (second panel fromInsulin Signaling in Muscle versus Insulin
the bottom) were assayed on muscle extracts from saline-injectedSignaling in Liver
(2) or insulin-injected (1) animals of the indicated genotypes as
Changes in insulin-stimulated signaling in skeletal mus- described in Figures 3A, 3B, and 3D. Detection of insulin-stimulated
cle tissue for the insulin receptor and IRS-1 were similar association of cellular tyrosine phosphoproteins with p85 (bottom
to those observed in liver of these different mutant mice. panel) was assessed by performing immunoprecipitation with an
anti-p85-specific antiserum followed by Western blot with an anti-Thus, insulin receptor expression and insulin-stimulated
phosphotyrosine antibody. Results shown are representative for 2–4tyrosine phosphorylation of the insulin receptor b sub-
independent experiments that gave similar findings.unit was reduced by 50% in the muscle of IR (1/2) and
IR/IRS-1 (1/2) mice (Figure 4, upper panel). Insulin-
stimulated tyrosine phosphorylation of IRS-1 and asso- antibody. As previously described, in the wild-type mice
the only signal detectable in this assay was a broadciation of p85 to IRS-1 was reduced by z50% in IRS-1
(1/2) and IR (1/2) mice and by z80% in IR/IRS-1 (1/2) band in the molecular weight range of z185 kDa, which
represents both tyrosine-phosphorylated IRS-1 andmice (Figure 4, middle panels).
Examination of IRS-2 expression and its tyrosine IRS-2 (Figure 4, lower panel). In IR (1/2) or IRS-1 (1/2)
mice, this signal was reduced by z50%, paralleling thephosphorylation upon insulin stimulation, however, re-
vealed an important difference in insulin signaling be- decrease in IRS-1 phosphorylation in these animals. In
the double heterozygote, the pp185 band was almosttween liver and muscle. While there was a significant
amount of IRS-2 detectable in liver extracts from mice undetectable, indicating that IRS-1 is the major insulin
signaling component in muscle mediating insulin stimu-of the different genotypes, immunoprecipitation from
muscle extracts using IRS-2-specific antisera revealed lation of PI 3-kinase and that very little tyrosine-phos-
phorylated IRS-2 is available to bind p85.a very weak signal, suggesting that IRS-2 expression in
muscle is low as compared to its expression in liver.
To address the question as to what extent insulin Consequence of Impaired Insulin
Signaling in IR/IRS-1 (1/2) Micestimulated association of p85 to any cellular tyrosine
phosphoprotein in muscle, we prepared anti-p85 immu- on Glucose Homeostasis
Despite the reductions in insulin receptor and IRS-1noprecipitates from muscle extracts and subjected
them to Western blotting with an anti-phosphotyrosine protein, there was no detectable difference in blood
for untreated animals; closed bars, values for insulin-treated animals.
(B) Insulin-stimulated tyrosine phosphorylation of IRS-1 was performed as described in (A), with the exception that immunoprecipitations
were performed using an anti-IRS-1-specific antiserum. The upper panel shows results of a typical experiment; the lower panel, the quantitation
of results obtained for at least four animals under each condition, expressed as in (A).
(C) Insulin-stimulated tyrosine phosphorylation of IRS-2 was assessed in a manner similar to that described for IRS-1 in part (B), except that
immunoprecipitations were performed with an anti-IRS-2-specific antiserum. The top panel shows a representative experiment; the bottom
panel, the quantitation of 4–6 animals for each experimental condition.
(D) Insulin-stimulated association of p85, the regulatory subunit of PI 3-kinase, with IRS-1 was assayed by performing immunoprecipitations
using an anti-IRS-1-specific antiserum, followed by Western blot analysis using an anti-p85-specific antiserum. The upper panel shows results
of a typical experiment; the lower panel, quantitation of four independent determinations for each experimental condition. Data are expressed
as percentage of the signal intensity obtained for the sample of the insulin-stimulated wild-type animal.
(E) Insulin-stimulated association of p85 with IRS-2 was assayed as described in part (D), with the exception that IRS-2-specific antisera were
used for the immunoprecipitations. The upper panel shows the result of an exemplary experiment; the lower panel, the quantitation of five
experiments presented as percentage of the intensity found in the insulin-stimulated wild-type animals.
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Figure 5. Effect of Heterozygosity for Insulin
Receptor and/or IRS-1 Deficiency on Glucose
Homeostasis
(A) Blood glucose concentrations were deter-
mined in random fed mice of the indicated
genotype using samples obtained from tail
biopsies at the age of 2 months. Data repre-
sent the mean blood glucose concentration
1/2 SEM for at least ten animals of each
genotype.
(B) Plasma insulin concentrations were deter-
mined for random fed animals at the age of
2 months. Blood was sampled by orbital
puncture from mice that had been anaesthe-
tized by an inhalation anaesthesia using me-
thoxyflurane. Insulin concentrations were de-
termined by RIA using rat insulin as a
standard. Data shownare the mean 1/2 SEM
of 8–12 animals for each genotype.
(C) Insulin tolerance tests were performed on
conscious 2-month-old animals. 0.75 U/kg
body weight of crystalline insulin were in-
jected in the peritoneal cavity. Blood glucose
concentrations were determined on blood
samples obtained by tail biopsy immediately
before and 15, 30, and 60 min after injection.
Results are expressed as percentage of
blood glucose concentration before insulin
injection and are the mean 1/2 SEM of 6–8
animals of each genotype: wild-type, closed
diamond; IRS-1 (1/2), closed square; IR
(1/2), open diamond; IR/IRS-1 (1/2), open
square.
(D) Plasma insulin concentrations were deter-
mined on random fed animals at the age of
4–6 months as described in (B). Data shown
are the mean 1/2 SEM of 10–12 animals for
each genotype.
(E) Insulin tolerance tests were performed on
conscious 4- to 6-month-old animals as de-
scribed in (C). Tests were performed on ani-
mals, which were normoglycemic over the
period before the test and exhibited blood
glucose concentrations in a range of the
mean 1/2 2 SEM of wild-type animals at the
day of the test. Results are the mean 1/2
SEM of 8–12 animals of each genotype: wild-type, closed diamond; IRS-1 (1/2), closed square; IR (1/2), open diamond; IR/IRS-1 (1/2),
open square.
(F) Blood glucose concentrations were determined in random fed mice at the age of 4–6 months. Data are shown for individual animals of
the indicated genotype and represent the mean blood glucose concentration obtained in at least two independent determinations. The shaded
area indicates the mean blood glucose concentration of wild-type animals 1/2 2 SD. The bar indicates the mean blood glucose concentration
for the indicated genotype.
glucose concentrations of IRS-1 (1/2), IR (1/2), and dramatically. Thus, by this age, the IR (1/2) mice exhib-
ited 5-fold elevated plasma insulin concentrations, andIR/IRS-1 (1/2) mice when examined shortly after birth
(data not shown) or at the age of 2 months (Figure 5A). those in IR/IRS-1 (1/2) mice were 13-fold elevated (Fig-
ure 5D). This insulin resistance was confirmed in theAt 2 months, however, insulin levels already suggested
an incremental effect of the two mutations on insulin insulin tolerance tests. Blood glucose levels in wild-
type mice fell by 45% over a 1 hr period following anresistance. Thus, insulin levels in the fed state were
increased z30% in IRS-1 (1/2) mice (n.s.), 1.9-fold in intraperitoneal injection of insulin, but dropped only by
30%–35% in IRS-1 (1/2) and IR (1/2) heterozygotesIR (1/2) mice (p , 0.05), and 2.6-fold (p , 0.05) in the
double heterozygotes as compared towild-type animals (Figure 5E). Even more dramatic results were obtained
when IR/IRS-1 (1/2) mice were examined. In thesemice,(Figure 5B). Intraperitoneal insulin tolerance tests per-
formed with 0.75 U/kg body weight, however, were not blood glucose concentrations dropped by z20% at 30
min after insulin injection and began to rise again by 1sensitive enough to detect a significant difference in the
blood glucose–lowering effect of exogenously adminis- hr. Thus, the double heterozygous mice were the only
group examined reaching statistical significance, astered insulin at this age (Figure 5C).
When the animals were reexamined between the ages compared to wild-type animals with regard to insulin
resistance in intraperitoneal tolerance testing (p , 0.01)of 4 and 6 months, insulin resistance had increased
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(Figure 5E). These data, together with the markedly ele- compared to wild-type animals (Figure 6B, left panel).
The b cell mass increased in parallel to the insulin resis-vated plasma insulin concentrations in IR/IRS-1 (1/2)
mice, indicate that two mild defects in the insulin signal- tance, but in no group did non-b cell mass differ from
wild-type mice (Figure 6B, right panel). Thus, there wasing cascade can act synergistically in producing insulin
resistance. a selective increase in b cells in these insulin resistant
mice. The enormous increase in b cells in the doubleAlso, over time, the insulin resistance produced by
two 50% defects in insulin signaling was sufficient to heterozygote animals resulted indistorted islet morphol-
ogy. In the wild-type mice, the non-b cells (20%–30%cause an increased rate of diabetes, even in theabsence
of obesity or overtb cell injury. Analysis of blood glucose of the islet) form a discontinuous mantle 1–2 cells thick
around a core of b cells (70%–80% of the islet) (Figureconcentrations revealed a tight range in which random
fed glucose concentrations were regulated in wild-type 6C). However, in the IR/IRS-1 (1/2) mice, the non-b
cells, which represent 8% of the islet, are scatteredanimals (Figure 5F). Blood glucose concentrations in
IRS-1 (1/2) were indistinguishable from those found in irregularly throughout the islet periphery (Figure 6C).
According to the multistep model of NIDDM, the oc-wild-type mice (Figure 5F). These data are consistent
with our previous findings that no wild-type or IRS-1 currence of diabetes can result from a relative or abso-
lute failure of pancreatic b cells tosecrete enough insulin(1/2) animal monitored in our laboratory over the past
three years has developed diabetes. Moderate insulin to overcome insulin resistance and maintain eugly-
cemia. When we compared additional IR/IRS-1 (1/2)resistance in the IR (1/2) mice resulted in the occur-
rence of hyperglycemia in some of these mice. While mice of known phenotype (diabetic or nondiabetic), the
most extensive b cell hyperplasia was found in the dia-most of them exhibited blood glucose concentrations
within the range of control animals, some mice exhibited betic mice. Indeed, the diabetic IR/IRS-1 (1/2) animals
had a mean random fed blood glucose value of 300 mg/mild hyperglycemia in the fed state (Figure 5F). Out of
40 animals characterized during the course of these dl (Figure 7A), a 15-fold increase in b cell mass (Figure
7B), and 21-fold elevated plasma insulin levels (Figurestudies, only four (10%) developed severe hyperglyce-
mia of more than 250 mg/dl on multiple individual deter- 7C) as compared to wild-type animals. In contrast, the
euglycemic double heterozygote mice had mean bloodminations. This rate of diabetes is consistent with an
incidence rate of diabetes of z10% when 150 IR (1/2) glucose values of 120 mg/dl (Figure 7A), a 3-fold in-
crease in b cell mass (Figure 7B), and a 4-fold elevationmice were studied in an independent animal facility (data
not shown). In contrast, IR/IRS-1 (1/2) mice showed a in plasma insulin levels (Figure 7C). Even so, the occur-
rence of diabetes indicates that the b cells were unablemarkedly increased incidence of disease. Thus, only
z40% were able to maintain glucose concentrations in to completely compensate for the insulin resistance
caused by heterozygosity of IR and IRS-1 null alleles.a normal range, several exhibited moderate hyperglyce-
mia, and 24 out of 61 IR/IRS-1 (1/2) mice (39.3%) be- Thus, there is a state of “relative” insulin deficiency in
which these double heterozygote animals were not ablecame overtly diabetic by the age of 6 months with blood
glucose concentrations of more than 250 mg/dl (Figure to maintain euglycemia. Whether absolute insulin defi-
ciency would develop over time remains to be deter-5F). Although IR/IRS-1 (1/2) mice of both genders were
highly insulin resistant and developeddiabetes, the male mined.
mice were more strongly affected than their female litter
mates (75% of the diabetic animals versus 25%). In
Discussionsummary, although a 50% deficiency in IRS-1 or in insu-
lin receptor alone causes diabetes in only a few mice,
Insulin and IGF-1 mediate a variety of essential signalsthese two defects act synergistically to cause a signifi-
for vertebrate growth and metabolism. The most promi-cantly increased incidence of disease.
nent function of insulin is the maintenance of eugly-
cemia, which is achieved by stimulation of glucose dis-
posal in muscle and fat and inhibition of hepatic glucoseIncreasing Degrees of Insulin Resistance
Cause Pancreatic b Cell Hyperplasia production. Longitudinal studies have shown that the
first step in the pathogenesis of NIDDM is resistanceand Hyperinsulinemia
In the multistep model for the pathogenesis of NIDDM, to insulin-stimulated glucose uptake in skeletal muscle
(Martin et al., 1992; Lillioja et al., 1993). Insulin resistanceinsulin resistance precedes the appearance of hypergly-
cemia and is accompanied by increased pancreatic in- can initially be overcome by elevated plasma insulin
concentrations, but after a period of time this mecha-sulin production. This situation is reflected in the pro-
gressively elevated insulin levels found in IR/IRS-1 (1/2) nism is no longer able to compensate sufficiently and
hyperglycemia occurs. The underlying molecular andmice. To assess the impact of different degrees of insulin
resistance on pancreatic compensation in these differ- genetic mechanisms for insulin resistance and the fac-
tors responsible for progression to frank diabetes areent mutant mice, we examined the pancreas histologi-
cally after immunostaining for insulin (Figure 6A) and still unknown. The animal model presented here indi-
cates that thecombination of minor defects in the insulindetermined pancreatic b cell and non-b cell masses by
point-countingmorphometry. In 6-month-old male mice, signaling cascade can act synergistically to cause insu-
lin resistance and NIDDM.even though there were no differences in body weight
or pancreatic weight, the b cell mass was increased 2- The double heterozygote IR/IRS-1 (1/2) mice model
fulfills three criteria that are not present in other rodentto 3-fold in IRS-1 (1/2) and IR (1/2) mice and 2- to
30-fold (mean 10-fold) in the IR/IRS-1 (1/2) mice as models but closely mimic human NIDDM. First, this
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Figure 6. Combined Deficiency for the Insulin Receptor and IRS-1 Has a Synergistic Effect on Pancreatic b Cell Hyperplasia
(A) Sections of pancreas of 6-month-old male mice of the indicated genotype were immunostained for insulin. Representative fields are shown
of animals exhibiting pancreatic b cell mass corresponding to the mean found for the respective genotype (bar 5 200 mm).
(B) Pancreatic b and non-b cell mass were quantitated by point-counting morphometrics on sections from 6-month-old male animals of the
indicated genotype. Data represent determinations for individual animals: wild-type, n 5 5; IRS-1 (1/2), n 5 4; IR (1/2), n 5 3; IR/IRS-1
(1/2), n 5 5. Animals at the appropriate age were randomly chosen for this experiment, blind for the diabetic phenotype. Pancreatic b cell
mass was significantly increased in IRS-1 (1/2) and IR (1/2) versus wild-type (p , 0.05).
(C) Immunostaining for non-b cell hormones of pancreas sections from a wild-type animal (left panel) and an IR/IRS-1 (1/2) animal (right
panel) (bar 5 100 mm).
model is polygenic in nature and is the result of rather for the IRS-1 deficiency, IR/IRS-1 (1/2) mice exhibit a
disproportionately severe insulin resistance in skeletalmodest genetic defects. NIDDM clearly has a genetic
component, and several studies suggest a polygenic muscle as compared to liver, mimicking the defect seen
in most individuals prior to development of NIDDM.nature of the disease. Metabolic defects in NIDDM,
whether genetic or acquired, are usually relatively mild; Third, the onset of diabetes is age-dependent. This also
reflects the typical course of human NIDDM, which isthese include the defects in signaling that occur with
mutant IRS-1 molecules or the decrease in signaling that rare before the age of 20 and gradually increases with
aging. In humans, this period can be accelerated byresults from insulin receptor down-regulation (Prince et
al., 1981; Olefsky et al., 1982; Caro et al., 1987; Almind obesity and/or sedentary life style, factors that might
also be superimposed in the NIDDM mouse. Therefore,et al., 1996). Second, the first detectable defect in our
model is resistance to the blood glucose–lowering effect the animals created reflect thus far the only rodent
model that represents the clinical picture of humanof insulin, and this can occur even in the absence of
obesity. Since skeletal muscle is responsible for 80% of NIDDM.
These characteristics of the NIDDM mouse provideinsulin-stimulated glucose transport, and since skeletal
muscle has a relatively low level of IRS-2 to compensate clues that may redirect research to find the underlying
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Figure 7. Pancreatic Hyperplasia and Hyper-
insulinemia Are Insufficient to Compensate
for Insulin Resistance in Diabetic Double Het-
erozygous Animals
Six-month-old male double heterozygote
mice of known phenotype were bled and then
sacrificed for morphometric analysis of pan-
creatic b cell mass. Mean fed blood glucose
concentrations for three individual nondia-
betic and three diabetic mice (A), plasma in-
sulin concentrations (B), and pancreatic b cell
mass (C). The shaded bar in each graph rep-
resents the mean 1/2 SEM detected in wild-
type animals in independent experiments.
defects in NIDDM humans. Research thus far has fo- of NIDDM. However, it is particularly difficult to test this
hypothesis in human populations, owing to the complex-cused on the identification of major gene effects caused
by mutations of the insulin receptor signaling network. ity of the gene pool and the possibility that even within
relatively homogenous populations, different genes mayThe animal model presented here suggests that minor
defects acting in concert with each other can cause interact in the pathogenesis of different individuals to
produce the insulin resistance and insulin secretory de-significant insulin resistance and overt NIDDM. Reduced
expression of the insulin receptor comparable to what fects.
The NIDDM mouse provides a practical demonstra-is seen in these mice (z50%) is found in tissues of
obese insulin-resistant people (Bar et al., 1976), diabetic tion of epistatic interactions among different genes in
the same pathway. The somewhat bimodal distributionpatients (Kolterman et al., 1981; Prince et al., 1981; Olef-
sky et al., 1982; Sinha et al., 1987), and most of the of glucose concentrations into diabetic and nondiabetic
animals suggests that only one or two additional genesobesity-linked rodent models of NIDDM (Kahn et al.,
1973). Likewise, previous studies have shown a reduc- may be required to give rise to a “clinically apparent”
phenotype. The phenotypic variation within each sub-tion of IRS-1 expression in both NIDDM and obesity in
humans and rodents (Saad et al., 1993; Goodyear et al., population may in part be explained by the mixed ge-
netic background (C57Bl/6J and 129 sv) used to derive1995), and this is of similar magnitude to that seen in
heterozygous IRS-1 deficiency. Furthermore, as noted the IR/IRS-1 (1/2) mice. It is likely that additional diabe-
tes susceptibility alleles are present in these two strains.above, IRS-1 sequence variations have been found with
an increased frequency in many diabetic populations Indeed, our use of mixed strains of mice was designed
to mimic as closely as possible the genetics of diabetes(Almind et al., 1993; Laakso et al., 1994; Clausen et
al., 1995). When expressed in cultured cells, the most in an outbred population. The identification of additional
susceptibility loci using quantitative trait linkage analy-common of these mutant IRS-1s exhibits an z30% re-
duction of insulin-stimulated PI 3-kinase activation (Al- sis on backcrosses of the NIDDM mouse should provide
information on the number and location of such locimind et al., 1996). While the relatively modest magnitude
of this defect might be considered of questionable bio- and suggest important syntenic regions for investigators
pursuing genome scans of NIDDM in human populationslogical significance, it is comparable to the defect seen
in IRS-1 (1/2) mice. Indeed, we have shown here that (Vaxillaire et al., 1995).
Another area of extensive research is the search forthis defect can act in concert with a second mild defect
in the insulin signaling cascade to cause progression pancreatic b cell growth and survival factors. We have
demonstrated that IR/IRS-1 (1/2) mice exhibit exten-toward NIDDM. It is likely that the combination of various
other defects in the insulin signaling cascade can cause sive b cell hyperplasia that allows for partial or complete
compensation of the severe insulin resistance by ele-a similar phenotype.
Another important implication from this mouse model vated plasma insulin levels. Since even the euglycemic,
nondiabetic animals exhibit up to 5-fold elevated b cellfor the genetics of NIDDM is the ability to use these
mice of a well-defined phenotype as an indicator for mass, this model may provide important clues for islet
growth and survival. As has been shown previously, bidentification of other genetic factors causing insulin
resistance. Since environmental factors within our ani- cell mass is dynamic and can compensate for increased
demand (Bonner-Weir, 1994). In double heterozygousmal colony are similar for all the mice, it seems likely
that genetic factors other than the knockout mutation animals at 1 month of age, little hyperinsulinemia is de-
tectable, and there is no b cell hyperplasia (data notinfluence the phenotype. The genetics of NIDDM in hu-
mans also follows a complex pattern of inheritance, indi- shown). Therefore, there must exist a b cell growth factor
that is able to stimulate the massive b cell proliferationcating that it is unlikely that NIDDM is caused by a single
mutation in a major gene. While different explanations in the young animals. Although glucose has been shown
to stimulate b cell growth (Bonner-Weir et al., 1989),have been set forth to account for this complex pattern
of inheritance, the notion that NIDDM may develop as this factor is probably something in addition to glucose,
since we can already detect a significant degree of isleta result of different mutations at different loci acting
simultaneously and in a synergistic manner (epistasis) cell hyperplasia in normoglycemic IR/IRS-1 (1/2) mice.
The mouse model presented here may help to identifyprovides a unifying hypothesis for the complex genetics
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Eli Lilly, Indianapolis, IN) (Montana et al., 1993), or for b cells, usingsuch b cell growth factors. On the other hand, there are
a guinea pig anti-porcine insulin antiserum (Linco, St. Louis, MO).mouse strains, such as the C57Bl/ks, that carry genes
b cell mass was measured by point-counting morphometry as pre-encoding a susceptibility for b cell failure. Breeding the
viously described (Bonner-Weir et al., 1989).
NIDDM mouse onto these background strains will
greatly facilitate the identification of such genes, since
Statistical Analyses
it is clear that the IR/IRS-1 (1/2) rely on massive b cell Each variable was analyzed using the unpaired Student’s t test. For
hyperplasia to maintain euglycemia for a period of time. all analyses, a p value of less than 0.05 was considered significant.
Results are given as means 1/2 SEM.Thus, there should be an increased rate or earlier onset
of NIDDM when the IR/IRS-1 (1/2) genotype is bred
Immunoprecipitations and Western Blot Analysesonto such a background, and analysis of these animals
of Insulin Signaling Proteinswill serve as a sensitive indicator for the presence of b
Immunoprecipitations and Western blot analyses of insulin signalingcell failure susceptibility genes.
proteins were performed on muscle and liver homogenates as pre-
In conclusion, we have created a novel polygenic viously described (Araki et al., 1994). Results are expressed as per-
model for the most common endocrine disease, NIDDM. centage of signal intensity seen in samples from insulin-stimulated
In many ways, NIDDM is similar to other common dis- wild-type animals.
eases such as atherosclerosis, hyperlipidemia, and obe-
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Note Added in Proof
While this paper was in press, two additional MODY genes were
identified as hepatic nuclear factors 1a and 4a:
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